GlassScriptPhysician profile
Madison P Lee
NPI 1437925971
$5,778.29
in general payments reported to CMS, 2019-2025
28 companies · $2,522 in 2025
The $2,522 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $486 · 2024: $2,771 · 2025: $2,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,778.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,052.22 | 2023-2025 | Rystiggo, Zilbrysq, Briviact |
| Abbvie INC. | $856.40 | 2024-2025 | |
| Emd Serono, INC. | $525.16 | 2023-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $523.35 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $495.65 | 2023-2025 | |
| Pfizer INC. | $309.29 | 2024-2025 | |
| Lilly USA, LLC | $208.89 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $203.34 | 2023-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $195.66 | 2024-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Neurocrine Biosciences, INC. | $192.93 | 2024-2025 | Ingrezza |
| Amgen INC. | $186.80 | 2025 | Uplizna |
| Mdd US Operations, LLC | $177.49 | 2024-2025 | Apokyn |
| Csl Behring | $136.18 | 2023-2024 | Hizentra |
| Argenx US, INC. | $126.02 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Kedrion Biopharma, INC. | $105.09 | 2023 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $87.37 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Eisai INC. | $63.45 | 2024-2025 | |
| Biogen, INC. | $58.25 | 2024-2025 | Spinraza, Skyclarys, Qalsody |
| Merz Pharmaceuticals, LLC | $54.57 | 2024-2025 | Xeomin |
| Takeda Pharmaceuticals U.S.A., INC. | $43.26 | 2025 | Hyqvia |
| Neurelis, INC. | $33.12 | 2023-2024 | Valtoco |
| Ipsen Biopharmaceuticals, INC | $27.89 | 2025 | Dysport |
| Genzyme Corporation | $24.16 | 2024 | |
| Lundbeck LLC | $21.38 | 2024 | Vyepti |
| Alnylam Pharmaceuticals INC. | $19.37 | 2024 | Amvuttra |
| Tanabe Pharma America, INC. | $19.36 | 2024 | |
| Nevro Corp. | $18.02 | 2024 | Senza |
| Mallinckrodt Hospital Products INC. | $13.62 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.